Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

EphA2 agonistic monoclonal antibodies and methods of use thereof

A technology of antibodies and human antibodies, applied in the fields of antibodies, chemical instruments and methods, anti-receptors/cell surface antigens/cell surface determinant immunoglobulins, etc., can solve problems such as difficult standard chemotherapy for cancer

Inactive Publication Date: 2007-01-31
MEDIMMUNE LTD +1
View PDF98 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As a result, many cancers are refractory to standard chemotherapy due to drug resistance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • EphA2 agonistic monoclonal antibodies and methods of use thereof
  • EphA2 agonistic monoclonal antibodies and methods of use thereof
  • EphA2 agonistic monoclonal antibodies and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0071] The present invention is based in part on the inventors' discovery that EphA2 monoclonal antibodies can suppress the phenotype of cancer cells. Reducing the activity of EphA2 selectively inhibits the growth of malignant cancer cells. EphA2 activity can be reduced with EphA2 agonistic monoclonal antibodies. While not wishing to be bound by any mechanism of action, this inhibition of cancer cell growth may be achieved by stimulating (ie, stimulating) EphA2 signaling to cause phosphorylation of EphA2 leading to its degradation. Reduced cancer cell growth was due to reduced EphA2 levels and ligand-independent EphA2 signaling.

[0072] Accordingly, the present invention relates to methods and compositions for the treatment, inhibition and management of cancer, particularly metastatic cancer. Particular aspects of the invention relate to methods and compositions comprising compounds that inhibit the proliferation and invasion of cancer cells, particularly those that overexp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to methods and compositions designed to treat, control or prevent cancer, particularly metastatic cancer. The methods of the invention comprise administering an effective amount of one or more antibodies that bind and stimulate EphA2, thereby increasing the phosphorylation of EphA2 and reducing the level of stimulated EphA2 in the cell. The invention also includes antibodies that bind preferentially to EphA2 epitopes exposed on cancer cells rather than non-cancer cells. The present invention also provides pharmaceutical compositions comprising only one or more EphA2 antibodies of the present invention, or the antibodies in combination with one or more other drugs for the treatment of cancer.

Description

1. Field of invention [0001] This application claims priority to U.S. Patent Provisional Application No. 60 / 524,177, filed November 20, 2003, which is a continuation-in-part of U.S. Patent Nonprovisional Application No. 10 / 436,783, filed May 12, 2003, This non-provisional application claims priority to U.S. Patent Provisional Application Nos. 60 / 379,368, filed May 10, 2002, 60 / 418,204, filed October 14, 2002, and 60 / 460,358, filed April 3, 2003, The entire contents of these patent applications are incorporated herein by reference. [0002] The present invention relates to methods and compositions for treating, controlling or preventing cancer. The methods of the invention comprise administering an effective amount of one or more EphA2-specific antibodies, preferably monoclonal antibodies, which are agonists of EphA2 and / or are capable of preferentially and selectively binding to cancer cells rather than non-cancer cells EphA2 epitopes exposed or increased in number. The inv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395C12P21/08C07K16/28C07H21/04A61KC07K16/24C07K16/30
CPCC07K16/2866C07K2317/565C07K16/24C07K2316/95A61K2039/505C07K16/3015C07K16/30C07K16/3069C07K2317/56A61P35/00A61P35/04C07K2317/75A61K39/395C07K16/18
Inventor 迈克尔·S·金奇凯利·卡尔斯-金奇简·C·斯图尔特
Owner MEDIMMUNE LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com